Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease

Empagliflozin is a novel type of sodium-glucose cotransporter two inhibitor with diverse beneficial effects in the treatment of nonalcoholic fatty liver disease (NAFLD). Although empagliflozin impacts NAFLD by regulating lipid metabolism, the underlying mechanism has not been fully elucidated. In th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yuting, Kan, Chengxia, Qiu, Hongyan, Liu, Yongping, Hou, Ningning, Han, Fang, Shi, Junfeng, Sun, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724565/
https://www.ncbi.nlm.nih.gov/pubmed/34992540
http://dx.doi.org/10.3389/fphar.2021.793586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724565/
https://www.ncbi.nlm.nih.gov/pubmed/34992540
http://dx.doi.org/10.3389/fphar.2021.793586

Ejemplares similares